OASM Oasmia Pharmaceutical AB

Oasmia recruits Michael of Winklerfelt as new CFO

Oasmia recruits Michael of Winklerfelt as new CFO

Michael af Winklerfelt has been appointed as new CFO of Oasmia Pharmaceutical AB. He will be a member of the management team and will take up his position on November 4.

Michael af Winklerfelt is 47 years old and was most recently with a British venture capital company, where in recent years he has worked with financial control as well as business and strategy development in a medtech company in the US.

He has wide-ranging international experience in the role of CFO from a number of industries and has previously worked for many years in China for Atlas Copco and its Group companies.

Michael af Winklerfelt will take up his position on November 4 and will replace Joakim Lindén, who has been acting CFO since March 2019.

For more information:

Urban Ekelund, IR Manager Oasmia

E-mail:

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops, manufactures and markets new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on Nasdaq in Stockholm and on the Frankfurt Stock Exchange.

Attachment

EN
30/10/2019

Underlying

OASMOasmia Pharmaceutical AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oasmia Pharmaceutical AB

Sean Conroy
  • Sean Conroy
OASM Oasmia Pharmace...

Vivesto - Termination of coverage

Edison Investment Research is terminating coverage on Vivesto (VIVE), Diurnal Group (DNL), Palace Capital (PCA), Primary Health Properties (PHP), Silver One Resources (SVE), Induction Healthcare (INHC) and Axiom European Financial Debt (AXI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

OASM OASMIA PHARMACEUTICAL AB
02/01/23 February 1, 2023 1 EN
Sean Conroy
  • Sean Conroy
OASM Oasmia Pharmace...

Vivesto - Turnaround strategy beginning to deliver

Vivesto capped off its 18-month strategic turnaround with reduced Q1 losses and a stated focus on its ‘string of pearls’ strategy to build its oncology pipeline through in-licensing and M&A. In March, it successfully completed a rights issue, generating net proceeds of SEK134.6m, extending its runway into 2024. This is sufficient to cover a number of clinical and commercial inflection points and execute its strategy. Key upcoming catalysts include the planned 2022 UK and German launches of Apeal...

OASM OASMIA PHARMACEUTICAL AB
06/27/22 June 27, 2022 1 EN
Sean Conroy
  • Sean Conroy
OASM Oasmia Pharmace...

Oasmia Pharmaceutical - Delivering on promises

FY21 results highlight delivery on key elements of Oasmia’s ongoing transformation. Notably, ‘rightsizing’ the business and prudent cost control has brought the underlying cash burn rate down to c SEK10m per month in 2021. With the fully secured rights issue expected to raise gross proceeds of c SEK150m, management has guided it can fund operations for 18–24 months. We anticipate material progression can be made across the pipeline during this time, with clinical progress expected from Cantrixil...

OASM OASMIA PHARMACEUTICAL AB
02/25/22 February 25, 2022 1 EN
Sean Conroy
  • Sean Conroy
OASM Oasmia Pharmace...

Oasmia Pharmaceutical - Rights issues secured and planned for Q122

Oasmia has announced it has secured a preferential, one-for-five rights issue that will raise gross proceeds of c SEK151m and should alleviate near-term funding requirements. The company’s largest shareholder has agreed to subscribe to its allotment (24.8%) and a consortium of external investors has guaranteed the remainder (75.2%), albeit on a 6.5% cash compensation basis. Subscription rights can be traded from 8 to 17 March. Oasmia has also announced plans to change its name to Vivesto; both t...

OASM OASMIA PHARMACEUTICAL AB
01/20/22 January 20, 2022 1 EN
Sean Conroy
  • Sean Conroy
OASM Oasmia Pharmace...

Oasmia Pharmaceutical - Rights issues secured and planned for Q122

Oasmia has announced it has secured a preferential, one-for-five rights issue that will raise gross proceeds of c SEK151m and should alleviate near-term funding requirements. The company’s largest shareholder has agreed to subscribe to its allotment (24.8%) and a consortium of external investors has guaranteed the remainder (75.2%), albeit on a 6.5% cash compensation basis. Subscription rights can be traded from 8 to 17 March. Oasmia has also announced plans to change its name to Vivesto; both t...

OASM OASMIA PHARMACEUTICAL AB
01/20/22 January 20, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch